Related Experiment Video
Updated: Jan 22, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
Apatinib, combined with chemotherapy or alone is effective in treating angiosarcoma: a case report
Mingyang Liu1, Yongmin Liu1, Huannan Guo1
1Department of Oncology, General Hospital of Heilongjiang Province Land Reclamation Bureau, Harbin.
Abstract:
Angiosarcomas are rare but aggressive tumors with poor prognosis. The treatment of angiosarcomas with vascular endothelial growth factor receptor inhibitors is still in the stage of clinical exploration. Herein we reported a patient of skin angiosarcoma with multiple organ metastasis. She was resistance to multiline chemotherapy and pazopanib but achieved remarkable shrinkage of the lesion after apatinib treatment combined with chemotherapy or alone. The progression-free survival of the primary lesion with KRAS V14I and RBM10 E119D mutations (10 months) was shorter than that of the brain without the mutation ( ≥ 12 months). Although it is not clear whether the KRAS V14I and RBM10 E119D mutations are the main factors that impact the effect of apatinib treatment or not, the results of this study will provide valuable clues for relevant follow-up basic and clinical studies.
Insights
A patient with metastatic skin angiosarcoma resistant to chemotherapy and pazopanib showed significant tumor shrinkage with apatinib treatment. This suggests apatinib
Area of Science:
- Oncology
- Medical Genetics
Background:
- Angiosarcomas are rare, aggressive vascular tumors with poor prognoses.
- Current treatment options are limited, and targeted therapies like vascular endothelial growth factor receptor inhibitors are under investigation.
Observation:
- A patient with metastatic skin angiosarcoma exhibited resistance to multi-line chemotherapy and pazopanib.
- Remarkable lesion shrinkage was observed following treatment with apatinib, alone or in combination with chemotherapy.
Findings:
- The patient's primary lesion, harboring KRAS V14I and RBM10 E119D mutations, had a shorter progression-free survival (10 months) compared to brain metastases without these mutations (≥12 months).
- This case highlights a potential differential response to apatinib based on mutational status.
Implications:
- Apatinib shows promise as a treatment for advanced angiosarcomas, particularly in cases resistant to standard therapies.
- Further research is warranted to elucidate the role of KRAS and RBM10 mutations in predicting apatinib efficacy in angiosarcoma.
- This study provides valuable insights for future clinical trials and therapeutic strategies for angiosarcoma.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Data Reporting and Recording
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...

